Bernstein initiated coverage on AbbVie with a new price target
$ABBV
Biotechnology: Pharmaceutical Preparations
Health Care
Bernstein initiated coverage of AbbVie with a rating of Mkt Perform and set a new price target of $203.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $205.00 | Buy → Neutral | Citigroup |
| 4/22/2025 | $210.00 | Overweight | Cantor Fitzgerald |
| 12/10/2024 | $191.00 | Neutral | BofA Securities |
| 12/5/2024 | $180.00 | Outperform → Neutral | Daiwa Securities |
| 11/22/2024 | $206.00 | Market Perform → Outperform | Leerink Partners |
| 11/15/2024 | $205.00 | Outperform | Wolfe Research |
| 11/4/2024 | Hold → Buy | Argus | |
| 10/17/2024 | $203.00 | Mkt Perform | Bernstein |
SCHEDULE 13G/A - AbbVie Inc. (0001551152) (Subject)
8-K - AbbVie Inc. (0001551152) (Filer)
11-K - AbbVie Inc. (0001551152) (Filer)
3 - AbbVie Inc. (0001551152) (Reporting)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
Select Business Owners Will Receive Access to Coaching, Mentorship, and Community During Exclusive 12-Week Virtual "Boostcamp"Additionally, 20 Entrepreneurs Will Each Receive a $20,000 Grant from BOTOX® CosmeticIRVINE, Calif., July 22, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project: Empowering Women Entrepreneurs. This initiative, led by BOTOX® Cosmetic, is aimed at closing the Confidence Gap and accelerating business growth for select entrepreneurs from across the country. This year's participants were selected from a pool of applicants representing a wide range of indust
Refresh Advanced OMEGA-3 Lubricant Eye Drops are the first eye drops on the market with omega-3 fatty acids MONTREAL, July 11, 2025 /CNW/ - AbbVie (NYSE:ABBV), announced today the availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada. The new, preservative-free eye drop is designed to provide rapid and long-lasting relief from dry eyes with the inclusion of natural omega-3 oil that helps lock in moisture. Proven to relieve dryness, stinging and discomfort, the Refresh Advanced OMEGA-3 Lubricant Eye Drop is the first eye drop on the market with Omega-3 fatty ac
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 /PRNewswire/ -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE:ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases. "Multispecifics including trispecific antibodies represent a bold new frontier in immuno
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
Citigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00
Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $210.00
BofA Securities resumed coverage of AbbVie with a rating of Neutral and set a new price target of $191.00
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:
NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –
NORTH CHICAGO, Ill., June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable August 15, 2025, to stockholders of record at the close of business on July 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tom
Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme